GSK
VP, Medicine Development Leader- Cancer Vaccines, Oncology Research Unit
$340K–$568K
Upper Providence +5 · Hybrid (Remote & On-site) · Director · Full-time · Posted Oct 21, 2026
- Location
- Upper Providence
GSK HQ
USA - Massachusetts - Waltham
UK - Hertfordshire - Stevenage
Switzerland - Zug
USA - Pennsylvania - Upper Providence - Experience
- No specific number of years stated.
- Education
- Advanced degree including MD, PhD, PharmD, MBA, MS.
About the job
Leads global development of GSK cancer vaccine medicines from late-stage transition through regulatory approval, launch and lifecycle management across indications and markets.
What you'll do
- Set the asset’s development strategy and lead a multidisciplinary global Medicine Development Team, coordinating R&D, regulatory, manufacturing, medical affairs and commercial functions.
- Manage development evidence, indication and combination strategies, portfolio decisions, resources, budget, risk and compliance through approval and lifecycle management.
- Represent the asset to senior governance groups and engage internal and external stakeholders, including regulators, clinicians, patients and collaborators.
What they ask for
- Advanced degree: MD, PhD, PharmD, MBA or MS.
- Oncology drug-development expertise in the global pharmaceutical or biotechnology industry, including experience leading successful medicine development and registration; experience with cancer vaccines, therapeutic vaccines or immuno-oncology combination products.
- Filing experience with BLA/NDA/MAA submissions as a core responsibility.
- Experience across the development/commercial lifecycle, including late-phase oncology development, and leading complex, global, matrixed teams.
Nice to have
- Experience with personalized medicine or novel vaccine manufacturing platforms, such as mRNA or neoantigen-based platforms.
- Familiarity with tumor immunology, antigen selection/neoantigen prediction, and immune monitoring/biomarker strategies.
Pay
USD $340,500 to $567,500 annual base salary
Tools
mRNA, BLA/NDA/MAA
Model-written summary · the original posting is authoritative